NES
CADX

New England Securities’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

New England Securities’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,450
Closed -$9K – 1794
2013
Q3 		$9K Buy
+1,450
New +$9.22K ﹤0.01% 1037

Other funds holding CADX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

New England Securities's CADX Position: Q4 2013 in Review

New England Securities sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 1,450 shares — an estimated $9K sold.

New England Securities first reported a position in CADX in Q3 2013 and held it in 1 quarter. The position peaked at $9K in Q3 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

  • New England Securities reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
  • New England Securities sold 1,450 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $9K.
  • New England Securities first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 1 quarter.
  • New England Securities's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $9K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on New England Securities's 13F filing for Q4 2013, filed 31 Jan 2014.